

PDA INDIA CHAPTER ANNUAL MEETING

Regulatory Expectations : The Quality Advantage

Agenda

Four Seasons Hotel
Bangalore

Day 1
21 February 2023

7:00 am – 7:45 am

Registration Open

Session 1

Opening Plenary Session and Keynote Presentations

8:00 am – 10:50 am

Session Leaders:

Vishal Sharma, President-PDA India Chapter,
Director, Vienni Training & Consulting LLP

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ FDA

Welcome and Opening Remarks

8:00am – 8:15am

Vishal Sharma, President-PDA India Chapter, Director, Vienni Training & Consulting LLP

Dr. Rustom Mody, PDA President Elect, SVP and Head R&D (Biologics), Sun Pharma Ltd.

Welcome, FDA Initiatives and Strategic Plans for the Region

8:15am – 8:45am

Dr. Sarah McMullen, Country Director, US FDA India Office

Mark Abdoo, Associate Commissioner, Global Policy and Strategy, US FDA

Regulatory and Inspectional Trends, a General Overview

8:45am – 9:15am

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ US FDA

9:15am – 10:05am

Inspection Trends during API Inspections; Current Approach for Remote Assessments by EDQM and EDQM's Approach on sharing of GMP Information, Assessment of CAPA and lifecycle Management of Sites involved in the CEP Scheme

Dr. Thomas Hecker, Inspector, EDQM

10:05am – 10:35am

Regulatory Trends in Aseptic Operations

Brooke Higgins, Senior Policy Advisor, Global Compliance Branch, CDER/OMQ/US FDA

10:35am – 10:50am

Question and Answers

10:50am – 11:15am

Refreshment Break

11:15am – 12:10pm

Session 2

Inspections, Record Requests, and other Agency Communications

Session Leader:

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ/ US FDA

11:15am – 11:50am

704 Record Requests and Other Agency Communications

Atul Agrawal, Supervisory Consumer Safety, ORA/OMPTO/US FDA – Virtual

Aditi Thakur, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA US FDA

Dr. Rebecca Frey-Cooper, Associate Director, CDER/OMQ/US FDA – Virtual

Panel Discussion

11:50am – 12:10pm

- **Atul Agrawal**, Supervisory Consumer Safety, ORA/OMPTO/FDA (Virtual)
- **Dr. Rebecca Frey-Cooper**, Associate Director, CDER/OMQ/FDA (Virtual)
- **Dr. Thomas Hecker**, Inspector, EDQM
- **Aditi Thakur**, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA/FDA
- **Saleem Akhtar**, Consumer Safety Officer, ORA/OMPTO/US FDA

12:10pm – 1:00pm

Networking Lunch

1:00pm – 2:40pm

Session 3

Internal Audits and Having a Robust and Sustainable Quality System

Session Leader:

Deva Puranam, Head-Global Quality Investigations, Surveillance & Regulatory Communications, Viatrix

1:00pm – 1:20pm

**Ensuring a Strong Corporate Oversight over a Multiple Site Organization
(Identifying gaps from site to site)**

Dr. Anil Sawant, Senior Vice President, Global Quality Compliance, Merck Sharpe & Dohme, USA; Chair-Elect Board of Directors, PDA Inc.

1:20pm – 2:10pm

Assuring Data Integrity in Commercial Drug Manufacturing and Drug Application Submissions: Regulatory Expectations and Challenges

Aditi Thakur, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA/FDA

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ FDA

Panel Discussion

2:10pm – 2:40pm

- **Dr. Carmelo Rosa**, Director Division of Drug Quality, CDER/OMQ FDA
- **Dr. Anil Sawant**, Senior Vice President, Global Quality Compliance, Merck Sharpe & Dohme, USA; Chair-Elect Board of Directors, PDA Inc.
- **Aditi Thakur**, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA/FDA

2:40pm – 2:55pm

Transitioning for next session and Short Break

2:55pm – 4:30pm

Session 4

Communicating with the Investigator, Auditor and Consultants

Session Leader:

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ FDA

2:55pm – 3:15pm

The Role of an Investigator

Saleem Akhtar, Consumer Safety Officer, ORA/OMPTO/US FDA

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ/US FDA

3:15pm – 3:35pm

The Role of an Auditor

Dr. Mary Farbman, Global Executive Director, QC, Merck Sharpe & Dohme, USA

The Role of a Consultant

3:35pm – 3:55pm

- **Gilda D'Incerti**, CEO & Founder, PQE Group
- **James (Jim) Johnson**, Partner, Sidley Austin LLP
- **Ivy Louis, Member**, Board of Directors, PDA Inc; Director-Vienni Training & Consulting LLP

Panel Discussion

3:55pm – 4:35pm

- **Gilda D'Incerti**, CEO & Founder, PQE Group
- **Dr. Mary Farbman**, Global Executive Director, QC, Merck Sharpe & Dohme, USA
- **Brooke Higgins**, Senior Policy Advisor, Global Compliance Branch, CDER/OMQ/FDA
- **James Johnson**, Partner, Sidley Austin, LLP
- **Ivy Louis, Member**, Board of Directors, PDA Inc; Director-VIENNI Training & Consulting LLP
- **Dr. Carmelo Rosa**, Director Division of Drug Quality, CDER/OMQ FDA
- **Aditi Thakur**, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA/FDA
- **Anil Arora**, President, Formulation Operations, Granules india

4:35pm – 4:45pm

Transitioning for next session and Short Break

Session 5

4:45pm – 6:15pm

Understanding Regulatory Expectations and a Deep Dive into the FDA OOS Guidance

Session Leader:

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ/US FDA

4:45pm – 5:15pm

Laboratory Controls

Saleem Akhtar, Consumer Safety Officer, ORA/OMPTO/US FDA

5:15pm – 5:30pm

Update OOS Guidance

Rebecca Parrilla, Consumer Safety Officer, CDER/OMQ/US FDA (Virtual)

21 February 2023

5:30pm – 6:15pm

How to Respond to a 483 Warning Letter/Import Alert Administrative Proceeding & Q&A
Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ/US FDA

6:30pm – 7:30pm

PDA India Chapter 10th Anniversary Recognition and Reception

*Day 2
22 February 2023*

8:00am – 9:30am

Session 6

CGMPs

Session Leader :

Brooke Higgins, Senior Policy Advisor, Global Compliance Branch, CDER/OMQ/US FDA

8:00am – 8:30am

Aseptic Process Controls and Expectations (Virtual)

Rick Friedman, Deputy Director for Manufacturing Quality, CDER/OMQ/US FDA

8:30am – 8:45am

Question and Answers

8:45am – 9:15am

Cleaning Validation Trends and Regulatory Expectations – What does Clean Mean?

Brooke Higgins, Senior Policy Advisor, Global Compliance Branch, CDER/OMQ/US FDA

9:15am – 9:30am

Question and Answers

9:30am – 9:45am

Refreshment Break

9:45am – 11:00am

Session 7

OOS Investigations

Session Leader:

Dr. Carmelo Rosa, Director Division of Drug Quality, CDER/OMQ FDA

OOS Investigations

- **Dr. Carmelo Rosa**, Director Division of Drug Quality, CDER/OMQ FDA
- **Aditi Thakur**, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA/FDA

Panel discussion/Question & Answers

- **Brooke Higgins**, Senior Policy Advisor, Global Compliance Branch, CDER/OMQ/FDA
- **Dr. Carmelo Rosa**, Director Division of Drug Quality, CDER/OMQ FDA
- **Aditi Thakur**, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA/FDA
- **Saleem Akhtar**, Consumer Safety Officer, ORA/OMPTO/US FDA

11:00am – 11:30am

Refreshment Break

Session 8:

Closing Session: Questions to the Regulators

Session Leader:

Dr. Anil Sawant, Senior Vice President, Global Quality Compliance, Merck Sharpe & Dohme, USA ; Chair-Elect-Board of Directors, PDA Inc.

11:30pm – 1:00pm

Presenters and Panelist:

- **Brooke Higgins**, Senior Policy Advisor, Global Compliance Branch, CDER/OMQ/FDA
- **Dr. Thomas Hecker**, Inspector, EDQM
- **Dr. Carmelo Rosa**, Director Division of Drug Quality, CDER/OMQ FDA
- **Aditi Thakur**, Senior Pharmaceutical Assessor, CDER/OPQ/OPMA/FDA
- **Saleem Akhtar**, Consumer Safety Officer, ORA/OMPTO/US FDA

Closing Remarks and Adjourn

Vishal Sharma, President-PDA India Chapter, Director, Vienni Training & Consulting LLP ; Conference Chair

1:00pm – 1:15pm

Rishikesh Jaiwant, Secretary - PDA India Chapter, Sr. Director, Manufacturing and Operations, Baxter India

Dr. Sumitra Pillai, Board Member -PDA India Chapter, VP, Head of R&D, Slayback Pharma

BONUS PRESENTATION – On-Demand

Data Integrity: Regulatory Expectations and Challenges

Peter Baker, Live Oak Quality Assurance
